Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant…
Rezolve Ai Gains Powerful Institutional Backing as Market Undervaluation Becomes Clear
Citadel, BlackRock, Vanguard, Jane Street, Northern Trust, Man Group, and State Street…
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
September 06, 2025 14:30 ET Â | Source: BridgeBio Pharma, Inc. - 80%…
Medidata Secures a Leader Position in Everest Group’s PEAK Matrix Assessment for eCOA, Driving the New Patient Experience Forward
Medidata eCOA was the highest Leader recognized in the evaluation, supporting over…
Kia America posts highest monthly sales in company history
Kia’s total sales in August reached 83,007 units, up 10.4 percent year-over-yearYear…
GGVL Relaunches V21 in 100% Recycled PET — India’s First Beverage Brand to Do So
From turning waste into want, to reshaping what premium looks like —…
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to…
Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
IMG Shares 2025 Autumn Travel Trends: Top Destinations and Increased Spending
IMG took a sample of its customers and reviewed more than 30,000…
Novo Nordisk A/S: Wegovy approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US…